Litcius/Paper detail

Effect of sotagliflozin on major adverse cardiovascular events: a prespecified secondary analysis of the SCORED randomised trial

Rahul Aggarwal, Deepak L. Bhatt, Michael Szarek, Christopher P. Cannon, Lawrence A. Leiter, Silvio E. Inzucchi, Renato D. Lópes, Darren K. McGuire, Julia B. Lewis, Matthew C. Riddle, Michael J. Davies, Phillip Banks, Amy Carroll, Benjamin M. Scirica, Kausik K Ray, Mikhail Kosiborod, David Z.I. Cherney, Jacob A. Udell, Subodh Verma, R. Preston Mason, Bertram Pitt, Philippe Gabríel Steg

2025The Lancet Diabetes & Endocrinology30 citationsDOI

Topics & Concepts

MedicineAdverse effectRandomized controlled trialInternal medicineMEDLINEIntensive care medicinePolitical scienceLawDiabetes Treatment and ManagementHyperglycemia and glycemic control in critically ill and hospitalized patientsMetabolism, Diabetes, and Cancer
Effect of sotagliflozin on major adverse cardiovascular events: a prespecified secondary analysis of the SCORED randomised trial | Litcius